Biomarker-Driven Lung Cancer
Latest News
November 19th 2024
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
More News
Updates in the Use of Liquid Biopsies for Multiple Tumor Types
July 12th 2018Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses updates in the use of liquid biopsies for multiple tumor types during the 2018 ASCO Annual Meeting.
Watch
Patel Considers a New Standard of Care When Treating Patients With NSCLC
July 6th 2018Jyoti D. Patel, MD, recently shared the treatment considerations and decisions she makes when treating patients with non–small cell lung cancer. Patel, professor of medicine and director of thoracic oncology at the University of Chicago Medicine in Illinois, discussed her treatment considerations for patients with NSCLC based on case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.
Read More
